Ibandronic Acid versus Zoledronic Acid in Cancer Patients with Skeletal Metastases Experiencing Moderate to Severe Pain

The purpose of the study is to investigate a new therapy for treating bone pain that results from cancer that has spread to the bones. The study compares treatment with ibandronic acid against treatment with another drug, zoledronic acid (a drug similar to ibandronic acid) to determine which drug is more successful in decreasing bone pain.

Official Title

A Study to Compare the Efficacy of Intravenous Loading Doses followed by Maintenance Treatment with Intravenous Ibandronic Acid versus Zoledronic Acid in Patients with Skeletal Metastases Experiencing Moderate to Severe Pain

Conditions

Metastatic Bone Pain

Study Type

Interventional

Study Design

Treatment

Further Details

Study Start

Eligibility & Criteria

Inclusion Criteria:- Diagnosis of cancer – Test results (X-ray, CT Scan or MRI) showing that the cancer has spread to the bone – Moderate to severe pain that corresponds to the area where the cancer has spread to the bone and the bone pain is being treated by a doctor with pain killers – No changes to the type of cancer chemotherapy for the past 6 weeks before the study starts – Adequate kidney function – Normal calcium levels in the blood Exclusion Criteria:- Patients with a high risk of fracturing a bone – Patients with cancer that has spread to the brain – Patients with Paget’s disease of bone – Patients who are receiving other investigational therapies – Patients who are pregnant or lactating

Total Enrolment

Contact Details

[1] Sydney, 2065, Australia [2] Newcastle, 2298, Australia australia.webmaster@roche.com